Patent Eligibility Bill May Carve Out Patenting Of Research
Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.
You may also be interested in...
Industry now needs to wait for a more appealing appeal or a revived legislative effort after the high court declines review of Athena Diagnostics v. Mayo Collaborative Services, which created a sharp divide in the Federal Circuit, and Hikma v. Vanda; biopharma and others contend eligibility issue is biggest problem in patent system.
Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.
BIO, PhRMA, AAM, former PTO Commissioners to testify at two-day Senate hearing on draft bill to revise Section 101 of Patent Act; ACLU coalition says legislation will allow patenting of human genes.